PANKU-Breast01 | #ESMO26
Iza-bren significantly improved PFS in pretreated HR+/HER2− advanced #BreastCancer vs physician’s choice chemotherapy (8.2 vs 4.0 months; HR 0.41).
@OncoAlert #bcsm
610 views · 19 likes · 7 reposts · 1 reply
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO The benefit came with substantial grade 3 or higher toxicity (85.3%) and frequent dose reductions (64.7%). OS remains immature. A strong efficacy signal, but tolerability, long-term outcomes, and optimal sequencing remain key considerations.
Source: Aya Mohamed | MSc, MD 🎗 · x.com